Calculated parenteral initial treatment of bacterial infections: Economic aspects of antibiotic treatment
- PMID: 32373428
- PMCID: PMC7186923
- DOI: 10.3205/id000047
Calculated parenteral initial treatment of bacterial infections: Economic aspects of antibiotic treatment
Abstract
This is the seventeenth chapter of the guideline "Calculated initial parenteral treatment of bacterial infections in adults - update 2018" in the 2nd updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience. This chapter analyses economic aspects of antiinfective therapy. Any treatment decision is also a cost decision. In this chapter the authors particularly analyse whether or not there is evidence that certain clinically effective strategies as Antimicrobial Stewardship programs (AMS), guideline adherent initial therapy, early diagnostics, De-escalation, sequence therapy or therapeutic drug monitoring also have benficial economic effects. These can be direct savings or shortening of length of stay to free resources.
Dies ist das siebzehnte Kapitel der von der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) herausgegebenen S2k Leitlinie „Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018“ in der 2. aktualisierten Fassung.Dieses Kapitel setzt sich mit den ökonomischen Effekten der antiinfektiven Therapie auseinander. Jede Behandlungsentscheidung ist auch eine kostenrelevante Entscheidung. Die Autoren beleuchten insbesondere die Frage, ob es Evidenz dafür gibt, das klinische wirksame Strategien auch ökonomisch günstig sind. Unter anderem werden Antibiotic Stewardship Programme (ABS), Leitlinienadhärenz in der Initialtherapie, De-Eskalation, Sequenztherapie sowie das therapeutische Drug Monitoring. Ökonomisch günstig sind sowohl direkte Kosteneinsparungen als auch die Verkürzung der Verweildauer um Ressourcen schneller wieder bereit zu stellen.
Copyright © 2020 Wilke et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics.GMS Infect Dis. 2020 Mar 26;8:Doc17. doi: 10.3205/id000061. eCollection 2020. GMS Infect Dis. 2020. PMID: 32373442 Free PMC article.
-
Calculated parenteral initial treatment of bacterial infections: Intra-abdominal infections.GMS Infect Dis. 2020 Mar 26;8:Doc13. doi: 10.3205/id000057. eCollection 2020. GMS Infect Dis. 2020. PMID: 32373438 Free PMC article.
-
Calculated parenteral initial therapy of bacterial infections: Bacterial meningitis.GMS Infect Dis. 2020 Mar 26;8:Doc07. doi: 10.3205/id000051. eCollection 2020. GMS Infect Dis. 2020. PMID: 32373432 Free PMC article.
-
Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy.Infect Drug Resist. 2013 Dec 18;7:1-7. doi: 10.2147/IDR.S25985. Infect Drug Resist. 2013. PMID: 24379684 Free PMC article. Review.
-
[The 2018 Update of the Recommendations of the Paul-Ehrlich-Society for Chemotherapy on the Initial Parenteral Therapy of Bacterial Diseases in Adults - What's relevant for Intensive Care?].Dtsch Med Wochenschr. 2019 Jun;144(11):729-733. doi: 10.1055/s-0043-114874. Epub 2019 Jun 4. Dtsch Med Wochenschr. 2019. PMID: 31163470 Review. German.
Cited by
-
Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade.Front Immunol. 2024 Jul 16;15:1424768. doi: 10.3389/fimmu.2024.1424768. eCollection 2024. Front Immunol. 2024. PMID: 39081318 Free PMC article. Review.
-
S2k guideline "Calculated parenteral initial treatment of bacterial infections in adults - update 2018", 2nd updated version: Foreword.GMS Infect Dis. 2020 Mar 26;8:Doc20. doi: 10.3205/id000064. eCollection 2020. GMS Infect Dis. 2020. PMID: 32373445 Free PMC article. No abstract available.
References
-
- Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, Zilber S, Donabedian S, Perri MB, Spalding J, Oster G. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010 Sep;48(9):3258–3262. doi: 10.1128/JCM.02529-09. - DOI - PMC - PubMed
-
- Retamar P, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, González-Galan V, Del Arco A, Pérez-Santos MJ, Téllez-Pérez F, Becerril-Carral B, Martín-Aspas A, Arroyo A, Pérez-Cortés S, Acosta F, Florez C, León-Ruiz L, Muñoz-Medina L, Rodríguez-Baño J SAEI/SAMPAC/REIPI Bacteremia Group. Predictors of early mortality in very elderly patients with bacteremia: a prospective multicenter cohort. Int J Infect Dis. 2014 Sep;26:83–87. doi: 10.1016/j.ijid.2014.04.029. - DOI - PubMed
LinkOut - more resources
Full Text Sources